|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **12Gy** | **CTLA** | **12Gy + IT-IC** | **12Gy + CTLA** | **12Gy + IT-IC + CTLA** |
| **Untreated** | 0.1302 | 0.9976 | **0.0045** | **0.0318** | **0.0006** |
| **12Gy** | N/A | 0.2815 | 0.6111 | 0.9754 | 0.1738 |
| **CTLA** | N/A | N/A | **0.0125** | 0.0801 | **0.0017** |
| **12Gy + IT-IC** | N/A | N/A | N/A | 0.9571 | 0.9476 |
| **12Gy + CTLA** | N/A | N/A | N/A | N/A | 0.5411 |

**Table S1.** ***P* values of pairwise comparisons of 9464D-GD2 tumor growth curves after treatment corresponding to Figure 3B.** *P* values of pairwise comparisons of tumor growth curves of untreated intradermal 9464D-GD2 tumors and tumors treated with RT alone, anti-CTLA-4 (CTLA) alone, RT and IT-IC, RT and anti-CTLA-4, or RT and IT-IC and anti-CTLA-4.